Background: Trigeminal neuralgia, known in Unani medicine as 'Isa & strns;ba", is a recurrent, excruciating pain affecting the areas innervated by one or more branches of the fifth cranial nerve. In Unani medicine, the principle of management of such headache disorders is expulsion of morbid humors and neuromodulation with drugs. Case presentation: Herein we describe a case of a 32-year-old female who reported to our hospital with severe paroxysmal pain on the right side of face. She had previously taken allopathic treatment, which gave temporary relief, and caused somnolence. She had been advised surgery, which she was skeptic of; hence, sought Unani treatment. At the time of presentation, the patient was in severe pain (indicated as 10 on NRS scale by her). Vital signs, local and systemic examination, laboratory and radiological imaging revealed no abnormality. Intervention and outcomes: The patient was prescribed Unani formulations containing ingredients such as Terminalia chebula Retz., Prunus amygdalus Batsch., Santalum album L., and Borago officinalis L., which exert many actions including neuroprotective, anxiolytic, general tonic, and pro-cognitive. Besides, she was advised wet-cupping therapy on the nape of neck and supra-scapular region. There was significant relief after the first session of wet-cupping and negligible symptoms after the 4th session. All medicines were discontinued after 4months, and the patient is symptom-free till date. Conclusion: The exceptional improvement in this case reiterates that Unani neuromodulator (Musakkin-e-A'sa & strns;b) drugs and wet-cupping may be a potentially effective and safe treatment option for Trigeminal Neuralgia. Larger studies are warranted to substantiate the observations.
Background: Integrative medicine intake requires a multidomain assessment. However, the necessary information is often scattered across electronic health records (EHRs), laboratory reports, clinical notes, and patient uploads, creating pre-visit and post-visit bottlenecks for care planning and insurance-support documentation.Objective: To introduce and evaluate a clinician-in-the-loop, automated, artificial intelligence (AI)-assisted intake model designed for data completeness, clinical usability, and reimbursement readiness improvement.Methods: To support the objectives, the system connects to compatible Fast Healthcare Interoperability Resources (FHIR)-compliant EHR and patient-portal sources, accepts patient uploads of fragmented records, consolidates available information, identifies gaps, generates adaptive intake questions, and prepares a clinician-facing summary. This quality-improvement evaluation examined information added or clarified after traditional intake, with manual verification against source records and patient responses. Automated laboratory interpretation and draft treatment strategies were assessed through clinician review.Results: Autonomous Health (AH) Intake recovered previously undocumented medication history and adverse reactions and organized functional limitations, safety concerns, and supporting test results for clinician review and prior-authorization submission. Using the methylation workflow as an example, we demonstrated that treatment strategies were approved without modification in 22/25 cases (88%); clinician review took approximately 10–15 minutes per completed case. In the separate laboratory test results evaluation, concordance with clinician review was 100% for 1927 extracted biomarker values and 72% (18/25) for overall care-plan summaries.Conclusions: The findings support the feasibility of automated, interactive, AI-assisted intake as a preparatory and documentation-support workflow for clinician review.
